APEIRON Biologics AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
23 Pages - GLDATA62529
$250.00

Summary

APEIRON Biologics AG (APEIRON) is a biotechnology company that concentrates on the development of biological and immunological solutions for the treatment of various cancers. It carries out projects in biotherapy and cancer immune field. The company’s lead project, APN311, is an antibody-based therapy used for the treatment of high-risk neuroblastoma, a cancer in children. Apeiron’s other clinical development projects caters to the treatment of relapsed/refractory high-risk neuroblastoma and other cancers; diseases resulting from an imbalance in the renin angiotensin system (RAS), inflammatory skin conditions and cancer through modulation of the immuno-reactivity of T cells. APEIRON is headquartered in Vienna, Wein, Austria.

APEIRON Biologics AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
APEIRON Biologics AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 10
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 11
Evotec Enters Into Co-Development Agreement With APEIRON Biologics 11
Licensing Agreements 12
Apeiron Biologics Enters into Licensing Agreement with Columbia University 12
Apeiron Biologics Enters into Licensing Agreement with Medison Pharma for APN311 13
Apeiron Biologics Enters into Licensing Agreement with Gen Ilac for APN311 14
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 15
Apeiron Biologics Enters Into Licensing Agreement With CCRI And SIOPEN For CH14.18 15
APEIRON Biologics Enters Into Option Licensing Agreement With Cleveland Clinic 16
Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 17
Asset Transactions 19
EUSA Pharma Acquires commercialization rights to Isqette from APEIRON Biologics 19
APEIRON Biologics AG - Key Competitors 20
Key Employees 21
Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Key Facts 1
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
APEIRON Biologics AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
APEIRON Biologics AG, Deals By Therapy Area, 2011 to YTD 2017 8
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 10
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 11
Evotec Enters Into Co-Development Agreement With APEIRON Biologics 11
Apeiron Biologics Enters into Licensing Agreement with Columbia University 12
Apeiron Biologics Enters into Licensing Agreement with Medison Pharma for APN311 13
Apeiron Biologics Enters into Licensing Agreement with Gen Ilac for APN311 14
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 15
Apeiron Biologics Enters Into Licensing Agreement With CCRI And SIOPEN For CH14.18 15
APEIRON Biologics Enters Into Option Licensing Agreement With Cleveland Clinic 16
Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 17
EUSA Pharma Acquires commercialization rights to Isqette from APEIRON Biologics 19
APEIRON Biologics AG, Key Competitors 20
APEIRON Biologics AG, Key Employees 21

List of Figures
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838